이상반응 보고

VAERS ID	2247504
성별	남성
나이	62세
주 코드	FR
제약회사	MODERNA
로트 번호
예방접종 횟수	1
접종일	2022-03-30
발병일	2022-03-31
상태	사망

증상

• 뇌출혈(Cerebral haemorrhage)

이환 중 질병

지병

Comments: Uric acid detected last year.

기타 의료

이전 예방접종

알레르기

임상 검사

증상 상세

Intracerebral hemorrhage; This regulatory authority case was reported by an other health care professional and describes the occurrence of CEREBRAL HAEMORRHAGE (Intracerebral hemorrhage) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.
Uric acid detected last year.
On 30-Mar-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.
On 31-Mar-2022, the patient experienced CEREBRAL HAEMORRHAGE (Intracerebral hemorrhage) (seriousness criterion death).
The cause of death was not reported.
It is unknown if an autopsy was performed.
For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
The patient received the first dose of COVID-19 (Moderna) vaccine at Clinic in the afternoon on March 30.
The patient could not be woken up at home at about 3 a.
m.
and was sent by an ambulance to our hospital for emergency treatment.
The patient was diagnosed for Central failure and Spontaneous intracranial hemorrhage.
Uric acid was detected in last year.
The patient died on April 2, 2022 Company Comment: This regulatory authority case concerns a 62-year-old old, male patient with no relevant medical history who experienced the fatal, unexpected, serious adverse event of special interest of Cerebral Hemorrhage.
The event occurred a day after receiving the first dose of mRNA-1273 vaccine.
It was reported that patient developed vomiting and loss of consciousness.
He was rushed to the emergency room where he arrived in a comatose state.
His blood pressure was extremely elevated and noted to have irregular respiratory pattern.
A cranial computed tomography scan was performed which showed intracerebral hemorrhage in the right basal ganglia with intraventricular extension.
Additional laboratory tests were done but the results were not specified.
Nicardipine drip, Sodium chloride venoclysis, Pantoprazole 80 mg IV and Tranexamic acid 500 mg IV were given.
There was no neurosurgical intervention performed.
He was admitted in the intensive care unit but died two days after the event started.
The cause of death was reported as central failure and spontaneous intracranial hemorrhage.
It is unknown if an autopsy was performed.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Event seriousness was assessed as per Regulatory Authority's report.
; Sender's Comments: This regulatory authority case concerns a 62-year-old old, male patient with no relevant medical history who experienced the fatal, unexpected, serious adverse event of special interest of Cerebral Hemorrhage.
The event occurred a day after receiving the first dose of mRNA-1273 vaccine.
It was reported that patient developed vomiting and loss of consciousness.
He was rushed to the emergency room where he arrived in a comatose state.
His blood pressure was extremely elevated and noted to have irregular respiratory pattern.
A cranial computed tomography scan was performed which showed intracerebral hemorrhage in the right basal ganglia with intraventricular extension.
Additional laboratory tests were done but the results were not specified.
Nicardipine drip, Sodium chloride venoclysis, Pantoprazole 80 mg IV and Tranexamic acid 500 mg IV were given.
There was no neurosurgical intervention performed.
He was admitted in the intensive care unit but died two days after the event started.
The cause of death was reported as central failure and spontaneous intracranial hemorrhage.
It is unknown if an autopsy was performed.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Event seriousness was assessed as per Regulatory Authority's report.